PLYMOUTH MEETING, PA — A new analysis of clinical trial data found that methylphenidate-based stimulants may provide measurable relief for cancer-related fatigue, adding evidence for a treatment approach oncologists have historically used cautiously because of limited large-scale clinical data.
The meta-analysis, published in the May issue of the National Comprehensive Cancer Network’s Journal of the National Comprehensive Cancer Network, reviewed nine randomized placebo-controlled clinical trials involving 823 cancer patients receiving either methylphenidate or dexmethylphenidate.
Researchers concluded the drugs produced statistically significant improvements in fatigue scores compared with placebo, with benefits becoming more pronounced after several weeks of treatment.
Cancer-related fatigue affects a majority of oncology patients and remains among the most difficult symptoms to manage, particularly for patients undergoing intensive treatment or living with advanced disease.
“What makes this finding particularly noteworthy is the time dimension,” said Bruno Almeida Costa. “The benefit isn’t fully apparent in the first couple of weeks, but by around five weeks it reaches a level that genuinely matters in terms of patients’ daily energy and function.”
Costa added that stimulant therapy should not replace longer-term interventions such as exercise programs, cognitive behavioral therapy, or mind-body approaches, but could instead “serve as a bridge” while those strategies take effect.
The analysis evaluated studies published between 2006 and 2024 involving adults with advanced cancer or individuals actively receiving cancer-directed treatment.
Most studies measured fatigue using the FACIT-F assessment scale, a standardized patient-reported questionnaire commonly used in oncology research.
Researchers also reported no statistically significant increase in adverse side effects compared with placebo, though the authors emphasized the need for careful patient selection and monitoring.
Methylphenidate, widely prescribed for ADHD and narcolepsy, has been on the U.S. market since 1955 and maintains one of the longest safety records among controlled prescription stimulants.
Costa argued the findings may carry particular relevance as cancer diagnoses increasingly affect younger adults balancing treatment with work and family responsibilities.
“For this population, fatigue can be especially disruptive because there’s so much they need and want to do,” Costa said.
Chandana Banerjee, who was not involved in the study, said the findings reinforce the importance of individualized treatment strategies and monitoring when using stimulant medications in oncology settings.
Current NCCN clinical guidelines already allow consideration of methylphenidate in certain cancer-related fatigue cases, though the organization advises caution regarding dosing and evaluation of underlying causes.
To read the full study, “Methylphenidate-Type Psychostimulants for Cancer-Related Fatigue: Updated Meta-Analysis of Randomized Controlled Trials,” visit JNCCN.org.
Separately, the journal disclosed it will discontinue print publication after its June 2026 edition and transition to a fully digital format beginning in July.
The publication also removed its article paywall, part of a broader effort to expand access to oncology research and accelerate dissemination of clinical findings.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.